一分钟看懂
这是一项关于Carcinoma的II 期研究，登记的药物或干预包括PF-08634404；Chemotherapy Regimen 1；Chemotherapy Regimen 2，当前状态为招募中。登记地点显示中国北京、广州、济南有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
PF-08634404；Chemotherapy Regimen 1；Chemotherapy Regimen 2 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital · 北京
- Guangdong Provincial People's Hospital · 广州
- The Affiliated Cancer Hospital of Shandong First Medical University · 济南
公开的入选条件
- * 18 years of age or older at screening.
- * Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy
- * PD-L1 status available based on local testing results
- * Adequate organ function
- * Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1
- * Part A only: Participants must have newly diagnosed, previously untreated, pathologically confirmed early-stage or LA (Stage II or IIIA/B), squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and America
- * Part B only: Participants must have pathologically confirmed early-stage or LA (Stage II or IIIA/B), squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer
- * Part C only: Participants must have pathologically confirmed LA, unresectable (Stage III) squamous or non-squamous NSCLC (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer TNM stagin
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07489066；登记信息更新于 2026-09-14。